Glycomic and Proteomic Profiling of Pancreatic Cyst Fluids Identifies Hyperfucosylated Lactosamines on the N-linked Glycans of Overexpressed Glycoproteins*

Pancreatic cancer is now the fourth leading cause of cancer deaths in the United States, and it is associated with an alarmingly low 5-year survival rate of 5%. However, a patient's prognosis is considerably improved when the malignant lesions are identified at an early stage of the disease and removed by surgical resection. Unfortunately, the absence of a practical screening strategy and clinical diagnostic test for identifying premalignant lesions within the pancreas often prevents early detection of pancreatic cancer. To aid in the development of a molecular screening system for early detection of the disease, we have performed glycomic and glycoproteomic profiling experiments on 21 pancreatic cyst fluid samples, including fluids from mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, two types of mucinous cysts that are considered high risk to undergo malignant transformation. A total of 80 asparagine-linked (N-linked) glycans, including high mannose and complex structures, were identified. Of special interest was a series of complex N-linked glycans containing two to six fucose residues, located predominantly as substituents on β-lactosamine extensions. Following the observation of these “hyperfucosylated” glycans, bottom-up proteomics experiments utilizing a label-free quantitative approach were applied to the investigation of two sets of tryptically digested proteins derived from the cyst fluids: 1) all soluble proteins in the raw samples and 2) a subproteome of the soluble cyst fluid proteins that were selectively enriched for fucosylation through the use of surface-immobilized Aleuria aurantia lectin. A comparative analysis of these two proteomic data sets identified glycoproteins that were significantly enriched by lectin affinity. Several candidate glycoproteins that appear hyperfucosylated were identified, including triacylglycerol lipase and pancreatic α-amylase, which were 20- and 22-fold more abundant, respectively, following A. aurantia lectin enrichment.

[1]  David H Perlman,et al.  Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. , 2009, Analytical chemistry.

[2]  C. McCulloch,et al.  Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. , 2007, AJR. American journal of roentgenology.

[3]  N. Rofsky,et al.  Prevalence of Incidental Pancreatic Cysts in the Adult Population on MR Imaging , 2010, The American Journal of Gastroenterology.

[4]  R. Dwek,et al.  Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. , 2007, Glycobiology.

[5]  H. Ueno,et al.  The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer , 2000, Pancreas.

[6]  R. Geyer,et al.  Carbohydrate structure of human pancreatic elastase 1. , 1991, The Biochemical journal.

[7]  M. Ohmuraya,et al.  Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor , 2009, Molecular Cancer Research.

[8]  Bhavinkumar B. Patel,et al.  Proteomic Analyses of Pancreatic Cyst Fluids , 2009, Pancreas.

[9]  Yehia Mechref,et al.  Solid-phase permethylation of glycans for mass spectrometric analysis. , 2005, Rapid communications in mass spectrometry : RCM.

[10]  J. Calam,et al.  Interactions of pancreatic secretory trypsin inhibitor in small intestinal juice: its hydrolysis and protection by intraluminal factors. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[11]  CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials , 2005, British Journal of Cancer.

[12]  S. Hakomori,et al.  Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain. , 1984, The Journal of biological chemistry.

[13]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[14]  Yehia Mechref,et al.  Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. , 2010, Analytical chemistry.

[15]  J. Neoptolemos,et al.  Prognosis of Resected Ampullary Adenocarcinoma by Preoperative Serum CA19-9 Levels and Platelet-Lymphocyte Ratio , 2008, Journal of Gastrointestinal Surgery.

[16]  M. Monden,et al.  Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas. , 1999, Journal of experimental & clinical cancer research : CR.

[17]  L. Mare,et al.  Suppression of beta 1,3galactosyltransferase beta 3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans. , 2004, European journal of biochemistry.

[18]  M. Dwek,et al.  A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[19]  U. Stenman,et al.  Application of proteomic technology in identifying pancreatic secretory trypsin inhibitor variants in urine of patients with pancreatitis. , 2006, Clinical chemistry.

[20]  Yehia Mechref,et al.  Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.

[21]  G. Badger,et al.  Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. , 2011, Gastrointestinal endoscopy.

[22]  S. Hakomori,et al.  Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. , 1986, Cancer research.

[23]  M. Hollingsworth,et al.  The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* , 2009, Molecular & Cellular Proteomics.

[24]  O. B. Schaffalitzky de Muckadell,et al.  Comparison of Plasma Tu-M2-PK and CA19-9 in Pancreatic Cancer , 2010, Pancreas.

[25]  P. Lescuyer,et al.  Role of proteomics to differentiate between benign and potentially malignant pancreatic cysts. , 2011, Journal of proteome research.

[26]  Y. Mechref,et al.  Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.

[27]  T. Nakagawa,et al.  Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.

[28]  U. Stenman Tumor-associated trypsin inhibitor. , 2002, Clinical chemistry.

[29]  M. Shah,et al.  Serum fucosylation changes in oral cancer and oral precancerous conditions , 2008, Cancer.

[30]  Y. Mechref,et al.  ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics. , 2008, Rapid communications in mass spectrometry : RCM.

[31]  L. A. van der Waaij,et al.  Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. , 2005, Gastrointestinal endoscopy.

[32]  R. Kannagi,et al.  Fucosylated type‐2 chain polylactosamine antigens in human lung cancer , 1988, International journal of cancer.

[33]  M. Sahin-Tóth,et al.  Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht's enzyme Y , 2007, Proceedings of the National Academy of Sciences.

[34]  H. Mischinger,et al.  Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA. , 1997, Hepato-Gastroenterology.

[35]  T. Oda,et al.  Overexpression of Sialyl Lewis x Antigen Is Associated with Formation of Extratumoral Venous Invasion and Predicts Postoperative Development of Massive Hepatic Metastasis in Cases with Pancreatic Ductal Adenocarcinoma , 2002, Pathobiology.

[36]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  Michelle A. Anderson,et al.  Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. , 2011, Journal of proteome research.

[38]  Ziding Feng,et al.  Glycosylation Variants of Mucins and CEACAMs As Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms , 2010, Annals of surgery.

[39]  N. Malats,et al.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients , 2011, European Journal of Epidemiology.

[40]  Osamu Ishikawa,et al.  Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation , 2006, International journal of cancer.

[41]  Kerby Shedden,et al.  Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. , 2007, Journal of proteome research.

[42]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[43]  J. Samra,et al.  CLASSIFICATION OF PANCREATIC CYSTIC LESIONS USING SELDI‐TOF MASS SPECTROMETRY , 2007, ANZ journal of surgery.

[44]  E. Małecka-Panas,et al.  Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis , 2011, Pancreatology.

[45]  B. Domon,et al.  Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. , 1988, Biochemistry.

[46]  J. Dagorn,et al.  Clinical assessment compared with cyst fluid analysis in the differential diagnosis of cystic lesions in the pancreas. , 1996, Surgery.

[47]  P. Banks,et al.  Practice Guidelines in Acute Pancreatitis , 2006, The American Journal of Gastroenterology.

[48]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[49]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.